Pharma Focus Asia

Fujifilm Invests US$40 million inNew State-of-the-Art Manufacturing Facility

Introduction:

FUJIFILM Corporation constructs new manufacturing facility for the development of viral vectors and advanced therapies with an investment of US$40 million. The new state-of-the-art manufacturing facility will be located at greater-Boston area.

Features:

The new facility is designed withexperimental and analytical equipment for the development of advanced therapies and viral vectors. Moreover, the site also plans of manufacturing services to beginearly phase clinical trialsafter the construction is completed.

This new facility will become the third location for viral vector CDMO services provided by FUJIFILM Diosynth Biotechnologies. In addition, the facility is particularly constructed in greater-Boston area due to the presence of more number of biopharmaceutical companies and thus enabling pharma communities to carry out cutting-edge research and innovation in the field of advanced therapies.

The new facility is expected to start its process development operations by the end of 2021 whereas the clinical trials are all set to begin in the site by 2023.

Specifications:

NameFUJIFILM Corporation
TypeNew Construction
BudgetUS$40 Million
Year2023
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference